DGDulcenombre Gómez-Garre

Dulcenombre Gómez-Garre

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dulcenombre Gómez-Garre has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Arturo Fernández-Cruz

    Facultad de Medicina, Department of Internal Medicine, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain

    5 shared publications
  • Paloma Muñoz-Pacheco

    Vascular Biology Research Laboratory, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos

    4 shared publications
  • Paloma Aragoncillo

    Department of Pathology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos

    3 shared publications
  • Adriana Ortega-Hernández

    Vascular Biology Research Laboratory, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos

    2 shared publications
  • Alicia Caro-Vadillo

    Department of Animal Medicine and Surgery, School of Veterinary Science, Universidad Complutense de Madrid

    2 shared publications
  • Jesús Egido

    Laboratory of Renal and Vascular Pathology, IIS-Fundación Jiménez Díaz, Universidad Autónoma

    2 shared publications

Latest Publications

  • Open Access

    Blood Pressure Control Is Associated with Moderate, but Not Necessarily High, Adherence to the DASH Diet in Older Adults

    by Rafael Luengo-Dilla, Adriana Ortega-Hernández, Mónica Álvarez-González, Javier Gutiérrez-Corral, Javier Modrego, Macarena Torrego-Ellacuría, Sergio de la Torre-Rodríguez, Imane Jeidane-Bentefrit, Julia García-García, María Soledad Fragua-Gil, et al.

    Background/Objectives: Hypertension control remains a global challenge. Evidence on the association between adherence to the Dietary Approaches to Stop Hypertension (DASH) diet and blood pressure (BP) control in older Mediterranean populations is limited. We aimed to assess this association in Spanish older adults. Methods: This cross-sectional analysis included 371 participants (69 ± 9 years). Dietary intake was assessed using a validated 146-item food frequency questionnaire (FFQ), and DASH diet adherence was categorized as low, medium, or high. Multivariable logistic regression models were used to examine associations with BP control. Results: Among participants with hypertension (n = 218), 52.8% achieved adequate BP control and consumed significantly more low-fat dairy products (+56%) and less sodium (−11%) than those with uncontrolled BP. The low adherence group had lower proportion of participants with controlled BP (21%) than the medium and high adherence groups (36% and 39%, respectively) (p < 0.05). Across increasing DASH diet adherence categories, systolic blood pressure (SBP) and diastolic blood pressure (DBP) were 4–5 mmHg and 3–4 mmHg lower, respectively. Medium adherence to the DASH diet was independently associated with substantially lower odds of uncontrolled BP (OR = 0.37; 95% CI: 0.16–0.82; p = 0.015). High adherence showed a similar magnitude of association but did not reach statistical significance. Conclusions: In this cohort of older Spanish adults, moderate adherence to the DASH diet was associated with meaningful improvements in BP control, suggesting that achievable, intermediate levels of DASH diet adherence may be sufficient to improve hypertension management in real-world settings. Longitudinal studies are needed to confirm causality and long-term cardiovascular benefits.


  • Eplerenone enhances cardioprotective effects of standard heart failure therapy through matricellular proteins in hypertensive heart failure

    by Paloma Muñoz-Pacheco, Adriana Ortega-Hernández, Alicia Caro-Vadillo, Sebastian Casanueva-Eliceiry, Paloma Aragoncillo, Jesús Egido, Arturo Fernández-Cruz, Dulcenombre Gómez-Garre

    Aims: The addition of an aldosterone receptor antagonist on top of current optimal therapy (based on angiotensin II inhibition) has demonstrated an important clinical benefit in heart failure patients with systolic dysfunction. Whether this finding also applies to heart failure patients with preserved systolic function is unknown. Therefore, we have studied the effect of adding eplerenone to standard pharmacological heart failure therapy (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker and diuretic and β-blocker) in the progression of heart failure in spontaneously hypertensive heart failure (SHHF) rats. Methods and results: Two-month-old SHHF rats were randomized to receive no treatment (SHHF group), a standard heart failure therapy (quinapril-torasemide-carvedilol; ST-SHHF group), or the combination of eplerenone and standard heart failure therapy (Eple+ST-SHHF group) for 20 months. Untreated SHHF was characterized by progressive left ventricular hypertrophy, fibrosis, and myocardial contractile and relaxation abnormalities, leading to pulmonary congestion. Despite similar blood pressure control, the addition of eplerenone to standard heart failure therapy further prevented left ventricular hypertrophy, contractile and relaxation alterations, and pulmonary congestion than standard heart failure therapy alone. ST-SHHF and Eple + ST-SHHF rats showed similar inhibition of structural extracellular matrix proteins collagen I, collagen III and fibronectin and metalloproteinase (MMP)-2, MMP-7, MMP-12, and MMP-13. However, only the coadministration of eplerenone with standard heart failure therapy normalized the expression of matricellular proteins thrombospondin 1, tenascin C, periostin, and secreted protein acidic rich in cysteine/osteonectin to values comparable to normotensive rats. Conclusion: In a hypertensive heart failure rat model, the addition of eplerenone to conventional heart failure therapy further improves cardiac structural and functional parameters, delaying the progression of heart failure. These beneficial effects of eplerenone were associated with normalization of matricellular protein expression.


  • Association of HIV-Infection and Antiretroviral Therapy With Levels of Endothelial Progenitor Cells and Subclinical Atherosclerosis

    by Dulcenombre Gómez-Garre, Vicente Estrada, Adriana Bsc Ortega-Hernández, Paloma Muñoz-Pacheco, Sergio Serrano-Villar, Mario Ávila, Manuel Fuentes-Ferrer, Teresa Tejerina, Arturo Fernández-Cruz

    Background: Although in the general population circulating vascular progenitor cell levels have been implicated in the homeostasis of the vascular wall through differentiation into endothelium and/or smooth muscle cells, it has not yet been assessed in HIV-infected patients. We herein investigated the number of progenitor cell subpopulations in HIV-infected patients and its relationship to carotid intima-media thickness (c-IMT). Methods: Blood samples were collected from 200 HIV-infected patients and CD34+/KDR+, CD34+/VE-cadherin+, and CD14+/Endoglin+ progenitor cells were identified by flow cytometry. c-IMT was determined by ultrasonography. A group of 27 healthy subjects was used as control group. Results: In our population (20 ART-naive patients and 180 treated patients), traditional cardiovascular risk factors were not found predictive of vascular progenitor cell levels. However, antiretroviral therapy (ART)-treatment was identified as the main predictive value for low CD34+/KDR+ cells and high CD14+/Endoglin+ cells after adjustment by cardiovascular risk factors (age, sex, hypertension, diabetes, and hyperlipidaemia) and HIV-related characteristics (HIV duration and ART treatment). Low levels of circulating CD34+/KDR+ or CD34+/VE-cadherin+ endothelial progenitor cells tended to be associated with increased c-IMT. However, a positive association was found between CD14+/Endoglin+ cells and c-IMT. Low number of CD34+/KDR+ cells was also associated with the longest exposure to nucleoside reverse transcriptase inhibitors and/or protease inhibitors. Conclusions: ART exposure is the main predictor of circulating vascular progenitor cell levels. However, their levels are only partially associated with high c-IMT in HIV-infected patients. ART has already been found to have proatherogenic effect, but our data first describe its relationship with vascular progenitor cells and c-IMT.


  • Ezetimibe inhibits PMA-induced monocyte/macrophage differentiation by altering microRNA expression: A novel anti-atherosclerotic mechanism

    by Paloma Muñoz-Pacheco, Adriana Ortega-Hernández, María Miana, Victoria Cachofeiro, Arturo Fernández-Cruz, Dulcenombre Gómez-Garre


  • Open Access

    Rosuvastatin Added to Standard Heart Failure Therapy Improves Cardiac Remodelling in Heart Failure Rats with Preserved Ejection Fraction

    by Dulcenombre Gómez-Garre, Ma Luisa González-Rubio, Paloma Muñoz-Pacheco, Alicia Caro-Vadillo, Paloma Aragoncillo, Arturo Fernández-Cruz

    Aims: Although statins may provide potential therapeutic pathways for patients with heart failure with preserved ejection fraction (HFpEF), no studies have evaluated statins in combination with standard HF therapy, which would reflect clinical practice more closely. To address this question, we evaluated whether rosuvastatin added to a standard HF therapy provides additional improvement in cardiac structure and function in rats with hypertensive heart failure (SHHF). Methods and results: Two-month-old SHHF rats were randomly assigned to four groups: (i) non-treated SHHF rats; (ii) rosuvastatin-treated SHHF rats; (iii) SHHF rats treated with quinapril plus torasemide plus carvedilol (considered as standard HF therapy); and (iv) SHHF rats treated with the combination of standard HF therapy and rosuvastatin. The administration of a standard anti-hypertensive HF therapy to SHHF rats for 17 months attenuated left ventricular (LV) chamber dilatation, cardiac hypertrophy, fibrosis, and inflammation compared with non-treated SHHF rats. Rosuvastatin alone prevented LV dilatation and cardiac inflammation similar to standard HF therapy-treated SHHF, despite being unable to normalize blood pressure (BP) or influence cardiac hypertrophy. However, and importantly, the addition of rosuvastatin to the standard HF therapy further prevented LV dilatation, preserved cardiac function, and normalized inflammation. Conclusion: These data show that the use of rosuvastatin plus a standard HF therapy results in a significant additional improvement in HF and cardiac remodelling in a rat model of HFpEF. These beneficial effects were independent of BP and plasma lipid changes, and seem to be due, at least in part, to decreased myocardial inflammation.


  • Open Access

    Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid‐lowering effect

    by D Gómez‐Garre, P Muñoz‐Pacheco, Ml González‐Rubio, P Aragoncillo, R Granados, A Fernández‐Cruz

    Background and purpose: Ezetimibe, a selective inhibitor of intestinal cholesterol absorption, might also suppress inflammatory components of atherogenesis. We have studied the effects of ezetimibe on two characteristics of atherosclerotic plaques (infiltrate and fibrosis) and on expression of inflammatory genes in a rabbit model of accelerated atherosclerosis.Experimental approach: Femoral atherosclerosis was induced by a combination of endothelial desiccation and atherogenic diet. Animals were randomized to ezetimibe (0.6 mg·kg−1·day−1), simvastatin (5 mg·kg−1·day−1), ezetimibe plus simvastatin or no treatment, still on atherogenic diet. A control group of rabbits received normolipidemic diet.Key results: Rabbits fed the normolipidemic diet showed normal plasma lipid levels. Either the normolipidemic diet or drug treatment reduced the intima/media ratio (normolipidemic diet: 22%, ezetimibe: 13%, simvastatin: 27%, ezetimibe + simvastatin: 28%), compared with rabbits with atherosclerosis. Ezetimibe also decreased macrophage content and monocyte chemoattractant protein‐1 expression in atherosclerotic lesions. Furthermore, ezetimibe reduced the increased activity of nuclear factor κB in peripheral blood leucocytes and plasma C‐reactive protein levels in rabbits with atherosclerosis. In THP‐1 cells, ezetimibe decreased monocyte chemoattractant protein‐1‐induced monocyte migration. Importantly, the combination of ezetimibe with simvastatin was associated with a more significant reduction in plaque monocyte/macrophage content and some proinflammatory markers than observed with each drug alone.Conclusions and implications: Ezetimibe had beneficial effects both on atherosclerosis progression and plaque stabilization and showed additional anti‐atherogenic benefits when combined with simvastatin. Its effect on monocyte migration provides a potentially beneficial action, in addition to its effects on lipids.


  • Activation of Peroxisome Proliferator-Activated Receptor-α and -γ in Auricular Tissue from Heart Failure Patients

    by Dulcenombre Gómez-Garre, Marta Herraíz, Ma Luisa González-Rubio, Rosa Bernal, Paloma Aragoncillo, Amparo Carbonell, Juan José Rufilanchas, Arturo Fernández-Cruz

    Objective: Peroxisome proliferator-activated receptors (PPARs), key transcriptional regulators of lipid and energy metabolism in cardiomyocytes, have recently been proposed to modulate cardiovascular pathophysiological responses in experimental models. However, there is little information about the functional activity of PPARs in human heart failure. Aims: To investigate PPAR-α and -γ expression and activity, and the association with ET-1 production and fibrosis, in cardiac biopsies from patients with end-stage heart failure due to ischemic cardiomyopathy (ICM) in comparison and from non-failing donor hearts. All samples were obtained during cardiac transplantation. Methods and results: Morphological analysis (by Masson trichrome and image analysis) did not detect fibrosis in the left atrium from non-failing donors (NFLA) or from ICM patients (FLA). However, left ventricles from failing hearts (FLV) contained a greater number of fibrotic areas (NFLA: 3.21±1.15, FLA: 1.63±0.83, FLV: 14.5±3.45%; n=9, P<0.05). By RT-PCR, preproET-1 expression was similar in the non-failing and failing atrium but was significantly higher in the ventricles from failing hearts (NFLA: 1.00±0.06, FLA: 1.08±0.11, FLV: 1.74±0.19; n=9, P<0.05). PPAR-α and PPAP-γ mRNA (by RT-PCR) and protein (by Western blot) levels were higher in the ventricles from failing hearts compared with the atrium from failing and non-failing hearts. Electrophoretic mobility shift assays showed that PPAR-α and PPAP-γ were not activated in the ventricles (NFLA: 1.00±0.11, FLA: 1.89±0.24, FLV: 0.95±0.07; n=9, P<0.05). Conclusions: These data suggest that PPAR-α and PPAP-γ are selectively activated in the atria from ICM patients and might be functionally important in the maintenance of atrial morphology.


  • Tight blood pressure control decreases apoptosis during renal damage

    by Karina Soto, Dulcenombre Gómez-Garre, Raquel Largo, Julio Gallego-Delgado, Nuria Tejera, Marina P. Catalán, Alberto Ortiz, Juan José Plaza, Covadonga Alonso, Jesús Egido